On October 2, SKB BIO fell 3.45% in regular trading, trading at 459.8 HKD/share, with turnover of approximately 28.95 million HKD.

The decline was primarily driven by broad-based selling pressure across the biotechnology sector. Within the sector, BEONE MEDICINES fell 7.01%, REMEGEN dropped 7.85%, 3SBIO declined 5.91%, INNOVENT BIO slid 5.05%, and AKESO lost 4.51%, reflecting a systemic sector downturn that weighed heavily on individual stocks including SKB BIO.

On the fundamental side, SKB BIO reported strong first-half results in August, with revenue of RMB 978 million and product sales surging 112% year-over-year to RMB 657 million. The company achieved its first-ever adjusted net profit of RMB 479 million. Multiple top-tier investment banks subsequently raised their target prices, with UBS setting a target of 678 HKD and BofA Securities at 644.4 HKD, both maintaining buy ratings. Additionally, the company recently announced that its TROP2 ADC sacituzumab (sac-TMT) had multiple Phase III studies selected for Late-Breaking Abstract presentation at the upcoming ESMO congress in October, which remains a near-term catalyst.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)